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Summary Treatment of malignant pleural mesothe-
lioma (MPM) depends on performance status of the
patient, tumor stage, and histological differentiation.
Chemotherapy (CHT) can be administered as first-
and second-line treatment in unresectable MPM or
as neoadjuvant or adjuvant treatment before or after
surgery. A combination of an antifolate and platinum-
based CHT is the only approved standard of care. Sev-
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eral targeted and immunotherapies are in evaluation
and further studies are warranted to determine the
therapeutic value of these new treatment options. Ra-
diotherapy (RT) can be considered either as adjuvant
treatment after surgery or for palliation of pain-related
tumor growth. Recent data support the use of RT in
a neoadjuvant setting. Macroscopic complete resec-
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Fig. 1 Postoperative situsafter extrapleural pneumonectomyof the right lungandpleura. Intensity-modulated radiotherapydose
plan. Coronal, sagittal, andaxial imageof the isodoseplan.Steepdose fall to the remaining left lung, liver, andkidney
tion by pleurectomy/decortication (P/D) or extrapleu-
ral pneumonectomy (EPP) is indicated in selected pa-
tients with good performance status. Surgery should
only be applied as part of a multimodality treatment
(MMT) in combination with chemo- and/or radio-
therapy. In a large number of cases, palliative attempts
are needed to improve quality of life and to achieve
symptom control.
Keywords Radiotherapy · Surgery · Multimodality
treatment · Palliative treatment · Chemotherapy
Introduction
Malignant pleural mesothelioma is a devastating dis-
ease and treatment is challenging. To date, there is
no worldwide agreement on standardized treatment
strategies. However, three treatment approaches—
either combined or as single treatment—have evolved
over the last decades: chemotherapy, radiotherapy,
and surgery. Furthermore, intracavitary strategies
such as intraoperative hyperthermic chemotherapy,
photodynamic therapy and intrapleural gene and
immunotherapy have been investigated as poten-
tial treatment options for local tumor control and
prevention of recurrence of disease.
In the following we describe each approach and
their combinations (multimodality protocols).
Chemotherapy
First-line treatment
The recommendations of a standard therapy with
platinum-based CHT in combination with modern
antifolates (pemetrexed or raltitrexed) are based on
two randomized trials published in 2003 and 2005
[1, 2]. The median overall survival (OS) in the
pemetrexed/cisplatin arm was 12.1 months versus
9.3 months in the control arm (p = 0.02). The me-
dian time to progression was significantly longer
in the pemetrexed/cisplatin arm (5.7 months ver-
sus 3.9 months; p = 0.001). Although the cisplatin
monotherapy was never compared to placebo in
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a randomized trial, these results enforced the recom-
mendation for a combination chemotherapy. Car-
boplatin can be used as an acceptable alternative to
cisplatin and may be better tolerated in elderly pa-
tients or patients with impaired functional status [3].
Other combination therapies as cisplatin + etoposide,
methotrexate or interferon were tested but overall
survival did not significantly improve compared to
the combination of cisplatin with antifolates [4]. In
principle, chemotherapy should be started as soon as
possible after diagnosis. The duration of chemother-
apy is 4–6 cycles of first-line therapy with cisplatin
and pemetrexed. The experiences with this regimen
derive from the treatment of NSCLC (Non-Small Cell
Lung Cancer), where a therapy of four cycles is rec-
ommend usually. Six cycles are favored only in case of
good overall response rates and lack of grade 3 and 4
toxicities.
Second-line treatment
For second-line therapy, no general recommendations
exist because little data is available in the literature.
A phase III evaluation of pemetrexed monotherapy
did not show any survival benefit compared to best
supportive care in previously treated patients [5].
However, there is evidence of better survival with
chemotherapy versus best supportive care [6]. Vi-
norelbine monotherapy has demonstrated a trend
towards improved OS in a phase II trial, as it was
shown in the first-line setting [7, 8]. Since there is
currently no standard second-line therapy, it is rec-
ommended to enroll patients in clinical trials.
Experimental approaches
Interleukins and interferons were tested in stud-
ies, as well as the application of targeted therapies
with monoclonal antibodies. None of the following
substances showed any survival benefit in several
studies: thalidomide, gefitinib, erlotinib, or imatinib
[9–14]. The first approach in combining bevacizumab
with cisplatin/gemcitabine failed to show any sur-
vival benefit [10]. However, recently presented data
of a randomized phase III trial combining cisplatin/
pemetrexed with bevacizumab showed significantly
improved progression-free and overall survival in
previously untreated unresectable MPM patients
[15]. The results of this study might lead to a new
paradigm in standard treatment in these patients.
Newer targeted therapies and immunotherapies as
tremelimumab or ipilimumab are currently under
investigation [16, 17]. Furthermore, the new PD-1 in-
hibiting agent pembrolizumab has shown promising
results in antitumor activity and randomized trials are
still ongoing [18].
Radiotherapy
Currently, the most intensive treatment regime for
pleural mesothelioma consists of a multimodal-
ity treatment combining chemotherapy, operation,
and radiotherapy. However, there is still discussion
whether patients actually benefit from the intensified
treatment, as the long-term outcome is still poor inde-
pendent of the combinations of treatment modalities.
There are curative and palliative intentions to treat
malignant pleura mesothelioma. In these settings
radiotherapy can be performed as neoadjuvant, ad-
juvant, and palliative radiotherapy. The introduction
of highly conformal radiotherapy technique (HCRT)
improved dose delivery and target coverage in com-
parison to conventional 3-dimensional conformal
radiotherapy (3DCRT).
Neoadjuvant radiotherapy
The concept of the preoperative neoadjuvant treat-
ment of the hemithorax can be performed for patients
with resectable pleural mesothelioma.
This concept (SMART) aims at inactivation of the
tumor and improvement of its resectability [19, 20].
Patients are treated with a hypofractionated radiother-
apy, which means the application of a higher dose of
5 Gy on 5 consecutive days with an integrated boost of
6 Gy to the macroscopic tumor. The target volume en-
compasses the whole lung including the visceral and
parietal pleura. To reduce the high dose to the organs
at risk as esophagus, liver, heart, or spinal cord, inten-
sity-modulated radiotherapy technique (IMRT), VMAT
(volumetric modulated arch therapy), or Tomotherapy
is the treatment of choice. After radiotherapy an ex-
trapleural pneumonectomy (EPP) has to be performed
within 8–10 days after the end of radiotherapy.
Adjuvant radiotherapy
Postoperative hemithoracic irradiation is regarded as
part of the three modality treatment concept which
combines chemotherapy, operation, and radiotherapy
for resectable malignant pleural mesothelioma. The
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dose of 50–54 Gy should be applied with a once daily
fraction of 1.8–2.0 Gy (Fig. 1).
Other fractionation schedules for 3D-conformal ra-
diotherapy are recommended as 25 × 1.8 Gy (45 Gy)
to the hemi thorax, followed by a boost onto the high-
risk area with 7 × 1.8 Gy (12,6 Gy); or as another alter-
native 23 × 2 Gy (46 Gy) to the hemithorax, followed
by 5 × 2 Gy boost which totals to 56–58 Gy for the
high-risk area. In case of IMRT 26 × 1.75 Gy (45.5 Gy)
with an integrated boost of 26 × 2.15 Gy (55.9 Gy) are
possible [21].
Dose constrains to the organs at risk (OAR; as the
non-involved lung, esophagus, spinal cord, liver or
gastrointestinal organs, kidneys) have to be respected
to avoid acute and long-term side effects as e. g.
esophagitis and pneumonitis.
Radiotherapy should be initiated between 4–12
weeks after surgery depending on the wound healing
process.
Palliative radiotherapy
For inoperable pleural mesothelioma, a palliative ra-
diotherapy treatment can be indicated with and with-
out chemotherapy.
In case of inoperability, generally it is not possible
to irradiate the whole hemithorax without damaging
the non-affected lung tissue. Therefore, the tumor can
be partially treated at regions where it causes pain or
at regions of high risk infiltration of spinal cord to
avoid side effects as paresis in the future. Treatment
time should be short, a 3D conformal radiotherapy or
IMRT can be applied with higher single dose (single
dose of 3–4 Gy up to a total dose of 30–40 Gy), taking
into account that parts of the tumor are not irradiated
and included into the clinical target volume (CTV).
Symptom-based radiotherapy treatments of metas-
tasis can be performed in all locations to control lo-
cal pain or neurological problems. Start of treatment
should be as soon as possible after presentation of the
patient to avoid longer hospitalization and to improve
quality of life. Doses of 3–4 Gy up to doses of 30 to
40 Gy or single doses of 8 Gy reduce the treatment
time as much as possible.
Re-irradiation with a reduced dose can be a treat-
ment option in case of local relapse taking into ac-
count the primarily applied radiation dose and the
dose at the OAR.
Surgery
Surgery for MPM can be applied in curative and pal-
liative intention. Macroscopic complete resection
(MCR) should be the goal of the respective surgical
procedure. Recently, combined treatment modalities
including radical surgery in terms of pleurectomy/
decortication (P/D) or extrapleural pneumonectomy
(EPP) are the most commonly used approaches for
treating MPM in curative intention. Due to the dif-
ficulty of large randomized trials only institutional
reports using different multimodality protocols and
different surgical techniques are available to discuss
whether P/D or EPP is the more appropriate proce-
dure to obtain better long-term survival in relation to
posttreatment quality of life.
After the IMIG 2012 meeting and much discussion
on the role of surgery and the value of macroscopic
complete resection the attendees agreed that (1) sur-
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gical macroscopic complete resection and control of
micrometastatic disease play a vital role in the mul-
timodality therapy of MPM, as it is the case for other
solid malignancies. (2) Surgical cytoreduction is in-
dicated when MCR is deemed achievable and (3) the
type of surgery (EPP or P/D) depends on clinical fac-
tors and on individual surgical judgment and exper-
tise [22].
Since the surgical technique of pleurectomy/decor-
tication (P/D) in the treatment of MPM includes a va-
riety of procedures with different clinical indications
and therapeutic intents, the International Association
for the Study of Lung Cancer (IASLC) and Inter-
national Mesothelioma Interest Group (IMIG) have
recently proposed a nomenclature for the different
techniques [23]. Partial pleurectomy was defined as
a cytoreductive procedure with partial removal of the
visceral and/or parietal pleurae without the intention
for macroscopic complete resection. P/D was defined
as complete resection of the parietal and visceral
pleurae and extended P/D as a technique with addi-
tional resection of the pericardium and diaphragm.
A recent systematic review assessing the safety and
efficacy of these techniques found that periopera-
tive mortality and morbidity ranged from 0–11% and
13–43%, respectively. Median overall survival ranged
from 7.1–31.7months and disease-free survival ranged
from 6–16 months [24]. A detailed analyses suggested
similar perioperative mortality outcomes between
different P/D techniques but a trend towards higher
morbidity and length of hospitalization for patients
who underwent extended P/D. However, overall and
disease-free survival appeared to favor extended P/D
compared to less aggressive techniques.
Extrapleural pneumonectomy (EPP) is a widely
standardized surgical procedure with en bloc resec-
tion of the parietal and visceral pleurae with the ipsi-
lateral lung, pericardium and diaphragm (Fig. 2) [25].
The role of EPP within multimodality approaches was
recently extensively discussed after the publication of
the Mesothelioma and Radical Surgery (MARS I) trial
which aimed to assess the clinical outcomes of pa-
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tients who were randomly assigned to EPP or no EPP
in the context of trimodal therapy [26]. The results of
the study suggested that radical surgery in the form
of EPP within trimodality therapy offers no benefit
and possibly harmed patients. However, the MARS I
trial was designed to assess the feasibility of such
a study and not to evaluate the risks and benefits of
EPP. In order to sufficiently answer this question an
actual number of 670 patients to identify a significant
survival benefit would have been needed. A recent
systematic review on the safety and efficacy of EPP for
patients with MPM including 58 studies reported that
median overall survival varied from 9.4–27.5 months,
and 1-, 2-, and 5-year survival rates ranged from
36–83%, 5–59%, and 0–24%, respectively. Overall
perioperative mortality rates were reported to range
from 0–11.8%, and the perioperative morbidity rates
from 22–82% [27]. Another recent retrospective eval-
uation of 3 high volume institutions including 251 pa-
tients completing EPP after platin-based induction
treatment reported a 30-day mortality of 5% and pe-
rioperative complication rate of 30% [28]. However,
according to the latest ERS/ESTS guidelines, EPP in
a curative intent should only be performed at high
volume centers in terms of a clinical study and within
a multimodal treatment algorithm [29].
Multimodality treatment
Since several studies have shown that surgical treat-
ment alone offers dismal prognosis only, multimodal-
ity approaches including chemo- and radiotherapy
have been suggested in order to improve survival.
Regarding the exact sequence of treatment modali-
ties there are no randomized trials available to an-
swer the question if chemo-, radio-, or combined
chemo/radiotherapy should be used as induction
treatment before surgery. With regard to EPP tri-
modality approaches, many high volume centers in-
clude chemotherapy as induction treatment followed
by surgery and then by hemithoracic radiotherapy
[30, 31]. The particular advantage of chemother-
apy before surgery is a possible reduction of tumor
load and downstaging, which may lead to a better
understanding of the individual tumor biology and
a more accurate patient selection. The possible ef-
fects of induction chemotherapy have recently been
studied in a prospective multicenter trial including
61 patients being considered surgical candidates at
diagnosis. Forty-five patients (74%) underwent EPP
and in 37 patients (61%) the resection was com-
plete. Postoperative radiotherapy was initiated in
36 patients. The median survival of all patients was
19.8 months. For the 45 patients undergoing EPP,
the median survival was 23 months [32]. Another
multimodal approach was recently introduced by the
Toronto group which is currently under investiga-
tion in the Surgery for Mesothelioma After Radiation
Therapy (SMART) trial. A short accelerated course
of high-dose hemithoracic intensity-modulated ra-
diation therapy (IMRT) is administered followed by
EPP [19]. In all, 25 patients with resectable clinical
stage T1-3N0M0 histologically proven, previously un-
treated MPM were included. Initial results revealed
a cumulative 3-year survival of 84% in epithelial
subtypes compared with 13% in biphasic subtypes.
Furthermore, the results suggested that this protocol
is feasible without elevated perioperative morbidity
and mortality. However, further prospective trials are
needed in order to investigate the value of different
multimodality strategies in the treatment of MPM.
Intracavitary treatment
Local recurrence is a frequent problem even after
macroscopic complete resection and occurs in up to
60% of the cases [31]. This may be caused by the in-
filtrative growing pattern of MPM to the surrounding
tissue and the inability to achieve 100% tumor-free
margins (R0 resection) after resection. Recently, ad-
ditional treatment approaches such as intracavitary
chemo-, immuno-, or photodynamic therapy have
been suggested to postoperatively secure resection
margins and to lower the risk of local recurrence.
Intracavitary photodynamic therapy (PDT) com-
bines a nontoxic photosensitizing compound with
visible light and can be delivered intraoperatively af-
ter P/D or EPP [33]. The concept of PDT combined
with radical pleurectomy was recently studied in
38 patients in predominantly stage III/IV disease with
a median survival of 31.7 months for all 38 patients
and 41.2 months for the 31/38 (82%) patients with
epithelial subtypes despite a median progression-free
survival (PFS) of 9.6 and 15.1 only [34].
It has been proven that hyperthermic intraopera-
tive chemotherapy (HIOC) is able to deliver a higher
local dose chemotherapy to the resected surface with
decreased toxicity compared to systemic therapy [35,
36]. The feasibility and effects of HIOC have recently
been investigated in several phase II trials and ex-
tended interval to recurrence and overall survival have
been reported in a group of patients with epithelioid
MPM and low risk factors [37–39]. Other intracavi-
tary concepts of binding cytotoxic (or other agents)
to a fibrin carrier are currently evaluated in phase I
and II trials. The concept of localized intracavitary
cisplatin–fibrin chemotherapy after MCR is evaluated
in a phase IIa trial to assess safety and toxicity of the
treatment (NCT01644994 Influence Meso) [40].
Patient selection and prognostic factors
Taken all this information together, patients under-
going MCR for MPM must be meticulously selected
in order to outweigh the benefits compared to the
potential risks. Several studies have been published
different prognostic factors and biomarkers for strat-
ifying patients into different prognostic groups. A re-
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cent systematic review of prognostic factors and pa-
tient selection reported that those with non-epithe-
lial MPM and nodal involvement have consistently
demonstrated to have a worse prognosis after EPP
[41]. Furthermore, several blood biomarkers have re-
cently been investigated to identify patients who will
benefit from surgical treatment. Among these, prein-
terventional C-reactive protein (CRP) was found to
predict benefit from multimodality treatment includ-
ing radical surgery [42]. Patients with elevated CRP
levels had a significantly shorter overall survival com-
pared with those with normal CRP, which was con-
firmed in multivariate analyses. In other recent stud-
ies biomarkers such as fibrinogen, albumin, or MPM
specific prognostic scores (currently under investiga-
tion, unpublished data) were reported to have prog-
nostic impact and could be useful in clinical decision
making [43, 44]. Moreover, a recent phase II study re-
ported that progression-free survival could be useful
as a prognostic marker for overall survival rather than
response rates to chemotherapy. Patient data from
10 European Organisation for Research and Treatment
of Cancer (EORTC) studies of first-line chemotherapy
in MPM were pooled and progression-free survival at
18 weeks after randomization was strongly correlated
and discriminated patients with better OS from the
poorer prognosis patients [45].
Finally, there is not much data available on the
quality of life (QoL) during and after treatment. A re-
cent study has included QoL data in their institutional
report and found a superiority of P/D over EPP in QoL
after 6 and 12 months [46].Thus, the MARS trial re-
ported that median quality of life scores were lower
in the EPP group than the no EPP group; however, no
significant differences between groups were reported
in the quality of life analyses [26].
However, since MPM is a very heterogeneous dis-
ease with variability of clinical symptoms, stage, his-
tology, tumor burden, and biological behavior, a mul-
tidisciplinary discussion of every patient considering
age, performance status, and individual prognosis
should be mandatory. All currently available thera-
peutic modalities in MPM are summerized in Table
1.
Palliative surgical procedures and symptom con-
trol
Usually, MPM is diagnosed at an advanced stage and
symptom control is an important part of every cu-
rative and palliative therapy attempt [47]. Common
symptoms are dyspnea due to pleural effusion (in
early stages) or lung encasement by pleural thicken-
ing (in later stages), weight loss, cough, and chest
pain caused by invasion of the thoracic wall. When
dyspnea is caused by pleural effusion early drainage
for symptom control is recommended followed by
pleurodesis at first relapse [29]. Sterile talc powder is
the preferred sclerosing agent for pleurodesis and can
be installed through a chest drainage or during diag-
nostic VATS biopsy if the lung completely comes to
expansion [29, 47]. Recurrent pleural effusions, espe-
cially in case of an entrapped lung can become more
difficult to manage and indwelling pleural catheters
may be the most practical way to manage recurrent
pleural effusions [48, 49]. Furthermore, VATS partial
pleurectomy (VATS-PP) has been suggested to im-
prove symptom control and survival. Recently, the
MesoVATS trial has randomized MPM patients to un-
dergo VATS pleurectomy vs. talc pleurodesis via an
indwelling intercostal chest drain or via thoracoscopy
[50]. VATS-PP did not significantly improve survival
and talc pleurodesis was considered to be preferable
due to fewer complications and shorter hospital stay.
However, VATS-PP significantly improved control of
recurrent pleural effusions in the first 6 months after
the procedure and improved QoL for 12 months.
Summary
At the time present, no worldwide accepted surgical
therapy exists and the choice of procedure depends
on tumor stage, clinical presentation, and especially
on institutional expertise and preferences. Pooling
of MPM patients in specialized centers is mandatory
to improve results of surgical treatment within mul-
timodality protocols. A proposed, stage-dependent
treatment algorithm is depicted in Fig. 3.
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